Heart failure & cardiomyopathies
Intravenous Iron Infusion in Patients with Heart Failure: A Systematic Review and Study-Level Meta-Analysis
Authors' conclusion
Intravenous iron infusion in patients with HF reduces the composite risk of first hospitalization for HF and CV mortality as well as the risks of first and recurrent hospitalizations for HF, with no effect on all-cause mortality or CV mortality alone.
Study context
- Population
- Patients with heart failure (HF) and iron deficiency
- Participants
- 3,438 patients10 randomized controlled trials (RCTs)
- Comparison
- IV iron infusion vs placebo or standard of care
- Outcome
- Composite of:
- Cardiovascular (CV) mortality
- First hospitalization for HF
Methodological detailsstudy-level, random effects, PubMed/Medline searched from inception till 6 November 2022
- Study-level
- Random effects
- PubMed/Medline searched from inception till 6 November 2022
Pooled result
As reported in the abstract
- Intravenous iron vs Placebo or standard of care: 95% CI 0.77–0.95
- Random-effects
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| First hospitalization for HF | 0.82 (0.67–0.99) | |
| Total hospitalizations for HF | 0.74 (0.60–0.91) | |
| All-cause mortality | 0.95 (0.83–1.09) | |
| 0.512Relative risk (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Intravenous Iron Infusion in Patients with Heart Failure: A Systematic Review and Study-Level Meta-Analysis. ESC Heart Fail. Published 2 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →